SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
NEUROCRINE BIOSCIENCES
(NQNM:NBIX Last Sale: 99.38 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (NBIX : $99.38)
$9,220,416 million Market Cap at Market Close, July 1, 2022
Employs 560.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
12790 El Camino Real Research Report Earnings Snapshot - Last 11/03/18
San Diego, CA 92130 Fact Sheet
Phone: (619)658-7600 Financial Statements
Peer Comparison
Annual Reports

Gary A. Lyons, Pres./CEO, Paul Hawran, CFO.
Develops therapeutics for the treatment of nerve disorders. IPO at $10.50 May 22, 1996. Raised $36.8 MM, selling 3.5 MM shares, 22% of the outstanding. Lead Manager: Robertson Stephens. Setback for insomnia drug May 16, 2006 when FDA said two doses of insomnia drug candidate Indiplon were "approvable," but a higher dose could not be approved; indicating 5-milligram and 10-milligram doses of indiplon have enough information to be approved, but a 15-milligram extended-release dose of the insomnia drug cannot be approved at this time.
Historical Charts    Technical Analysis
No Historical Data available for NBIX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common NBIX $99.38 $99.38 0 .0 $94.46 $99.55 702,585 $94.46 $99.55 92,779,393
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock #############

A273
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex